The Longevity Fund, based in San Francisco, was founded in 2011 by Laura Deming with a mission to fund companies focused on developing drugs for age-related diseases and ultimately for longevity. The fund has supported pioneering companies in the field and is now launching a new fund under a new name, led by GP Alex Colville, to continue driving innovation in the longevity industry.
With a vision for the future of longevity research, The Longevity Fund envisions three key stages in the field's development: Pioneers (2013-2023), Dominant players (2023-2050), and Generic players (2050 and beyond). The fund believes that mission-oriented founders with unconventional backgrounds will play a critical role in advancing the field and bringing about breakthroughs in human longevity through innovative drug development.
Generated from the website